The burden of HIV, tuberculosis, malaria, diabetes, cardiovascular diseases, viral hepatitis, neglected tropical diseases (NTDs), and vaccine-preventable diseases, including hepatitis, is high in Africa. For instance, according to the WHO, in 2020, an estimated 886,000 adults and children were newly infected with HIV. The annual number of new HIV infections also climbed in the Middle East and North Africa (source: UNAIDS data 2021). In 2020, 25.6 million people were living with HIV in the African Region, out of which 20.6 million were in Eastern and Southern Africa, 4.7 million in Western and Central Africa, and 230,000 in the Middle East and North Africa (source: UNAIDS Data 2021). Furthermore, the burden of malaria is also high in Africa, and it is a significant cause of morbidity and mortality in Nigeria. According to the World Malaria Report 2021, in 2020, Nigeria accounted for 27% (≈61 million) and 32% (≈200,000) of the estimated global malaria cases and deaths, respectively.
There is a frequent outbreak of endemic diseases in Nigeria. According to an article published by the United States Agency for International Development (USAID) in September 2022, Malawi is a high-burden malaria country with an annual incidence rate of 332 cases per 1,000 people, and around 4.8 million cases of malaria are reported per year.
Similarly, the burden of non-communicable diseases is large in Africa. According to the International Diabetes Federation (IDF) Diabetes Atlas 2021, in 2021, 24.0 million people (aged 20–79 years) were living with diabetes in Africa. The number of people with diabetes in Africa is expected to increase by 129% to reach 55 million by 2045 (source: IDF Diabetes Atlas 2021). Furthermore, in 2021, an estimated 2,013,000 people (aged 20–79) were living with diabetes in Algeria. This number is projected to reach 3,497,900 by 2045. Out of the total number of people with diabetes in 2021, it is estimated that 40.2% of people are living with undiagnosed diabetes. An estimated 2,884,000 people (aged 20–79) are living with diabetes in Tanzania. The number of people (aged 20–79) living with diabetes is growing at a CAGR of 14.7% from 2011–2021 (source: IDF Diabetes Atlas 2021).
The governments in African countries have been taking various steps to tackle the burden of diseases and promote awareness amongst the people of Africa. For example, in October 2020, the Government of Nigeria, with the support of the WHO, developed and launched the “National Malaria Strategic Plan 2021-2025”. This strategic plan was launched with a vision to achieve less than 10% malaria prevalence and reduce its mortality to less than 50 deaths per 1,000 live births by 2025. Furthermore, in June 2022, the U.S. Embassy in Nairobi (Kenya) announced the approval of USD 345 million in funding through the United States President’s Emergency Plan for AIDS Relief program (PEPFAR) to support Kenya's HIV response. The funds allocated through the PEPFAR Country Operational Plan (COP) 2022 will be used from October 1, 2022, through September 30, 2023, to support critical solutions required to maintain epidemic control in Kenya. Thus, the high burden of diseases and the rising number of initiatives to tackle the burden of diseases and promote awareness has resulted in the increased demand for IVD test in Africa.
According to this latest publication from Meticulous Research®, the Africa in vitro diagnostics market is expected to grow at a CAGR of 4.8% from 2022 to 2029 to reach $1.78 billion by 2029.
Key companies operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).
Meticulous Research’s Repository for In Vitro Diagnostic Industry Include:
Africa IVD Market by Product & Services, Technology (Immunoassay, Point of Care, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), Customer Type - Forecast to 2029
IVD Contract Manufacturing Services Market by Type (Assay Development, Manufacturing), Category (Reagents, Systems), Technology (Immunoassay, Molecular Diagnostics, Clinical Chemistry, Hematology, Microbiology, Urinalysis) - Global Forecast to 2028
In Vitro Diagnostic (IVD) Reagents Market by Type (Antibodies, Oligonucleotide, Nucleic Acid Probe), Technology (Immunoassay, Hematology, Microbiology), Use (Research, Analyte Specific Reagent), End User (IVD Manufacturer, Clinical Laboratory) - Global Forecast to 2027
In-vitro Diagnostics Market (IVD Market) by Product & Solution (Consumables, Systems, Software & Services), Technology (ELISA, Rapid Tests, PCR, Microbiology), Application (Infectious Diseases, Oncology), End User (Hospitals, Diagnostic Laboratories) – Forecast to 2027